What strategies might boost SLNO's EPS in 2025?

To boost Soleno Therapeutics' EPS in 2025, the company could implement several strategic initiatives: 1. **Commercial Success of VYKAT XR**: The FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome (PWS) presents a significant opportunity. A successful commercial launch and market penetration could lead to increased revenues, thereby boosting EPS. 2. **Market Expansion and Sales Force Growth**: Soleno's plans to deploy a sales team of 30 representatives suggest a strategic focus on market expansion. As the sales force grows and matures, it could lead to improved sales and potentially higher revenues. 3. **Pricing Power**: The company's weight-based pricing strategy for VYKAT XR, with an annual Wholesale Acquisition Cost (WAC) significantly higher than anticipated, indicates a strong pricing power. This could translate to higher gross margins and, consequently, higher EPS. 4. **Potential for Additional Indications**: While currently focused on hyperphagia in PWS, Soleno's proprietary technology and expertise in biochemical innovation suggest a potential for developing treatments for other indications. Achieving additional approvals could diversify revenue streams and boost EPS. 5. **Financial Discipline**: Soleno's prudent use of cash and financial resources, as evidenced by its cash holdings and operating cash flow, positions the company well to invest in growth opportunities that could enhance EPS without overextending its financials. By focusing on these strategic areas, Soleno Therapeutics can optimize its operations and financial performance, potentially leading to a significant boost in EPS in 2025.